Breakthrough treatments offer hope for melanoma patients, with promising results from clinical trials and ongoing research. Melanoma survival rates have doubled since 2009, and new treatments like oncolytic viruses, fecal transplants, and engineered antibodies are showing encouraging outcomes. According to the American Cancer Society's annual report, the five-year survival rate for distant-stage melanoma has increased from 18% in 2009 to 35% in the 2014-2020 period. However, skin cancer rates among seniors are projected to skyrocket over the next 25 years, with some forms expected to increase by more than 140%.
New research has revealed why some patients stop responding to immune checkpoint inhibitors. UCLA researchers found that DNA changes enable tumor cells to evade self-destruction signals from the immune system. Melanoma tumors undergo large-scale DNA alterations, disabling cellular self-destruction mechanisms and erasing genes that would normally cause cancer cells to die while making extra copies of genes that prevent cell death.
Exciting developments in melanoma treatment include a next-generation oncolytic virus, a genetically engineered herpes simplex virus type 1 (HSV-1), which shrank advanced melanoma tumors. This therapy, RPI (vusolimogene oderparepvec), contains a strain of HSV-1 engineered with a protein that assists with fusion (GALV-GP-R-) and granulocyte-macrophage colony-stimulating factor (GM-CSF). In a trial, one-third of patients experienced a 30% reduction in tumor size, and uninjected tumors also shrank or disappeared, with an objective response rate of 32.9%. A global phase 3 trial is ongoing, and Replimune has resubmitted its biologics license application to the FDA.
Early research for melanoma includes fecal microbiota transplants using healthy donor stool, which, in a small phase 1 study, resulted in patients surviving over four years when combined with standard immunotherapy. Another potential therapy is an engineered CD40 antibody, 2141-V11, which can trigger a systemic immune response when injected into tumors. In a phase 1 trial, six out of 12 patients with advanced cancers that had spread to the skin experienced tumor shrinkage, with two achieving complete responses lasting over a year.
Additionally, a wearable patch for cancer detection is being developed, which measures distinct electrical patterns to determine whether moles or lesions are cancerous. This device, developed by Mohammad J. Moghimi, Ph.D., can detect differences in electrical properties between healthy skin and cancerous areas, providing valuable information beyond visual inspection.
